Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)
Study Details
Study Description
Brief Summary
This is a pilot, randomized, placebo-controlled trial of omega-3 fatty acids in autism. Autism, originally described by Kanner in 1943, is among the most severe of neurodevelopmental disorders. It is a Pervasive Developmental Disorder (PDD) affecting social and communicative functions and is also characterized by repetitive behaviors/restricted interests. It is also frequently accompanied by significant aggression, self-injury, irritability and hyperactivity, making care for these individuals an even greater challenge for families or institutional settings. Autism severely impacts the affected individual and family members, causing life-long functional impairment. In this protocol the investigators will use the terms "autism" and "autism spectrum disorder (ASD)" interchangeably to refer to Autistic disorder, Asperger Syndrome and PDD-Not Otherwise Specified (NOS).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Currently risperidone is the only medication approved the by Food and Drug Administration (FDA) for this disorder, and specifically for irritability associated with autism, although not all patients with autism respond to risperidone. No pharmacologic treatments have been approved for use in preschool children, although it is clear that early intervention is associated with improved outcomes. Behavioral and educational therapies play a significant role in the management of autistic symptoms. The history of alternative treatments in autism is notable for the exaggerated benefit of a variety of supplements, such as high dose vitamins (e.g. B6, magnesium), and secretin. The current widespread use of alternative/nutritional supplements to patients with autism without scientifically demonstrated efficacy, underscores the necessity for scientifically sound studies to be conducted. Complementary and alternative medical therapies (CAM) are commonly employed by families of autistic children. Recent surveys have estimated the prevalence of such use to be between 30% and 95% (1,2,3). Omega-3 fatty acids were reported to be used in 28.7% of patients (1). However, only two small case series and a very small randomized study have been reported in this population to date. The investigators propose to conduct a randomized controlled trial of omega-3 fatty acids in preschoolers with ASD.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Omega-3 Fatty Acids Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. |
Dietary Supplement: Omega-3 Fatty Acids
Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
Other Names:
|
| Placebo Comparator: Placebo Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. |
Dietary Supplement: Placebo
Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score [Baseline and 24 Weeks]
The PDDBI measures autism symptomology. The autism composite score was used as the primary outcome measure for autism symptom severity. PDDBI Autism Composite Scale Range: Minimum Range = 10 (lower autism symptom severity) Maximum Range = 100 (higher autism symptom severity) The Autism Composite is calculated from the sum of T-scores of the Sensory/Perceptual Approach Behaviours, Ritualisms/Resistance to Change, Social Pragmatic Problems, and Semantic/Pragmatic Problems domains subtracted by the sum of T-scores of the Social Approach Behaviours, and Expressive Language domain then converted into the Autism Composite as a T-score. Mean change between baseline and week 24 is reported. A negative change indicates improvement
- Change From Baseline in the Behaviour Assessment System for Children (BASC-2) - Externalizing Problems Composite [Baseline and 24 Weeks]
The BASC-2 externalizing problems composite measures hyperactivity and aggressive behaviours. Primary Outcome domain: Externalizing Problems composite Externalizing Problems Composite T-Score Range: Minimum Range: 10 (lower externalizing problems) Maximum Range: 120 (higher externalizing problems) The Externalizing Problems composite is computed from the sum of t-scores from the hyperactivity and aggression subscales then converted into the externalizing problems composite t-score. Mean change between baseline and week 24 is reported. A negative change indicates improvement.
Secondary Outcome Measures
- Number of Participants Classified as Responders by the Clinical Global Impression - Improvement (CGI-I) [24 weeks]
The CGI-I is a seven-point scale that provides a clinician rating of global improvement and as such is already inherently a measure of change. It requires the clinician to assess the degree to which the participant's illness has improved or worsened relative to a baseline state before the intervention. Change is rated as: 0- Not assessed Very Much Improved Much Improved Minimally Improved No Change Minimally Worse Much Worse Very Much Worse Participants are classified as responders if their CGI-I score was 1 or 2 and non-responders for CGI-I scores of 3 to 7.
- Change From Baseline in the Vineland Adaptive Behavioral Scales (VABS) - Adaptive Functioning Composite [Baseline and 24 Weeks]
The VABS is a measure of adaptive behavior in daily settings. Secondary measure domain: The adaptive functioning composite describes an individuals overall functioning Adaptive Behaviour Composite Standard Score Range: Minimum range: 20 (low adaptive functioning) Maximum range: 160 (high adaptive functioning) The adaptive behaviour composite standard score is computed from the sum of standard scores from the communication, daily living skills, socialization and motor skills domains and converted into the adaptive behavior composite standard score. Change in the adaptive behaviour composite standard score from baseline to week 24 is reported. Positive change indicates improvement.
- Change From Baseline in the Preschool Language Scale (PLS-4) - Total Language [Baseline and 24 Weeks]
The PLS-4 is a language measure that provides a global assessment of a child's language functioning abilities, receptive and expressive language. Secondary outcome measure domain: Total language standard score Total Language Standard Score Range: Minimum range: 50 (lower language abilities) Maximum range: 150 (higher language abilities) The total language standard score is computed from a sum of the auditory comprehension and expressive communication standard scores, then converted into the total language standard score. Change of total language standard scores from baseline to week 24 is reported. Positive change indicates improvement
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female outpatients 2-5 years of age.
-
Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV) criteria. DSM-IV criteria for an autism spectrum disorder, (Autistic disorder, Asperger syndrome or PDD-NOS) will be established by a clinician with expertise with individuals with ASD based on parent interview, Autism Diagnostic Observation Schedule (ADO) and Autism Diagnostic Interview (ADI-R)
-
If already receiving stable non pharmacologic educational, behavioral, dietary and or/ natural health product interventions during the preceding 3 months prior to Screening, will not electively initiate new or modify ongoing interventions for the duration of the study unless the child's condition is worsening or their turn comes up on the treatment waiting list.
-
Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.
-
The parents must be able to speak and understand English sufficiently to allow for the completion of all study assessments.
Exclusion Criteria:
-
Patients born prior to 35 weeks gestational age.
-
Patients with any primary psychiatric diagnosis other than autism at Screening. We are aware the most primary psychiatric disorders are unlikely to be diagnosed in this age group
-
Patients with a medical history of neurological disease, including, but not limited to, epilepsy/seizure disorder (except simple febrile seizures), movement disorder, tuberous sclerosis, fragile X, and any other known genetic syndromes, or known abnormal MRI/structural lesion of the brain.
-
Patients with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, or coagulation deficits.
-
Patients taking psychoactive medication(s) (e.g.,stimulants, antidepressants, antipsychotics, antiepileptics, anxiolytics, clonidine).
-
Patients that have been off pharmacotherapy for less than 6 weeks.
-
Patients who are participating in another clinical trial
-
Patients on anticoagulants
-
Patients who know that they will initiate or change nonpharmacologic interventions during the course of the study.
-
Patients unable to tolerate venipuncture procedures for blood sampling.
-
Patients taking Omega-3 supplements who have not discontinued treatment for six weeks prior to entering into the study.
-
Patients who have allergies to any of the ingredients in omega-3 (study product) or the placebo.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Holland Bloorview Kids Rehabilitation Hospital | Toronto | Ontario | Canada | M4G 1R8 |
Sponsors and Collaborators
- Evdokia Anagnostou
- Holland Bloorview Kids Rehabilitation Hospital
- The Hospital for Sick Children
Investigators
- Principal Investigator: Evdokia Anagnostou, M.D., Holland Bloorview Kids Rehabilitation Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 09-018
Study Results
Participant Flow
| Recruitment Details | Participants were recruited from the hospital clinical database, as well as presentations at local conferences and media. Diagnosis was established using the Diagnostic and Statistical Manual, Fourth Edition for an Autism Spectrum Disorder supported by the Autism Diagnostic Observations Schedule and the Autism Diagnostic Interview - Revised. |
|---|---|
| Pre-assignment Detail | Participants were randomized to the two arms in a 1:1 fashion by the pharmacy, based on a randomization schedule produced by the study biostatistician. They were stratified into one of four strata based on the PDDBI score obtained at screening (four quartiles). |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Period Title: Overall Study | ||
| STARTED | 19 | 19 |
| COMPLETED | 15 | 17 |
| NOT COMPLETED | 4 | 2 |
Baseline Characteristics
| Arm/Group Title | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. | Total of all reporting groups |
| Overall Participants | 19 | 19 | 38 |
| Age (Count of Participants) | |||
| <=18 years |
19
100%
|
19
100%
|
38
100%
|
| Between 18 and 65 years |
0
0%
|
0
0%
|
0
0%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
4
21.1%
|
6
31.6%
|
10
26.3%
|
| Male |
15
78.9%
|
13
68.4%
|
28
73.7%
|
| Region of Enrollment (participants) [Number] | |||
| Canada |
19
100%
|
19
100%
|
38
100%
|
Outcome Measures
| Title | Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score |
|---|---|
| Description | The PDDBI measures autism symptomology. The autism composite score was used as the primary outcome measure for autism symptom severity. PDDBI Autism Composite Scale Range: Minimum Range = 10 (lower autism symptom severity) Maximum Range = 100 (higher autism symptom severity) The Autism Composite is calculated from the sum of T-scores of the Sensory/Perceptual Approach Behaviours, Ritualisms/Resistance to Change, Social Pragmatic Problems, and Semantic/Pragmatic Problems domains subtracted by the sum of T-scores of the Social Approach Behaviours, and Expressive Language domain then converted into the Autism Composite as a T-score. Mean change between baseline and week 24 is reported. A negative change indicates improvement |
| Time Frame | Baseline and 24 Weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 participant was dropped from the analysis in the Omega-3 group as there was insufficient data due to early termination. |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Measure Participants | 18 | 19 |
| Mean (95% Confidence Interval) [units on a scale] |
-4.5
|
-6.4
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Omega-3 Fatty Acids, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.5 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Title | Change From Baseline in the Behaviour Assessment System for Children (BASC-2) - Externalizing Problems Composite |
|---|---|
| Description | The BASC-2 externalizing problems composite measures hyperactivity and aggressive behaviours. Primary Outcome domain: Externalizing Problems composite Externalizing Problems Composite T-Score Range: Minimum Range: 10 (lower externalizing problems) Maximum Range: 120 (higher externalizing problems) The Externalizing Problems composite is computed from the sum of t-scores from the hyperactivity and aggression subscales then converted into the externalizing problems composite t-score. Mean change between baseline and week 24 is reported. A negative change indicates improvement. |
| Time Frame | Baseline and 24 Weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 participant was dropped from the analysis in the Omega-3 group as there was insufficient data due to early termination. |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Measure Participants | 18 | 19 |
| Mean (95% Confidence Interval) [units on a scale] |
3.2
|
-3.0
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Omega-3 Fatty Acids, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.02 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Title | Number of Participants Classified as Responders by the Clinical Global Impression - Improvement (CGI-I) |
|---|---|
| Description | The CGI-I is a seven-point scale that provides a clinician rating of global improvement and as such is already inherently a measure of change. It requires the clinician to assess the degree to which the participant's illness has improved or worsened relative to a baseline state before the intervention. Change is rated as: 0- Not assessed Very Much Improved Much Improved Minimally Improved No Change Minimally Worse Much Worse Very Much Worse Participants are classified as responders if their CGI-I score was 1 or 2 and non-responders for CGI-I scores of 3 to 7. |
| Time Frame | 24 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 participant was dropped from the analysis in the Omega-3 group as there was insufficient data due to early termination. |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Measure Participants | 18 | 19 |
| Number [participants classified as responders] |
12
63.2%
|
12
63.2%
|
| Title | Change From Baseline in the Vineland Adaptive Behavioral Scales (VABS) - Adaptive Functioning Composite |
|---|---|
| Description | The VABS is a measure of adaptive behavior in daily settings. Secondary measure domain: The adaptive functioning composite describes an individuals overall functioning Adaptive Behaviour Composite Standard Score Range: Minimum range: 20 (low adaptive functioning) Maximum range: 160 (high adaptive functioning) The adaptive behaviour composite standard score is computed from the sum of standard scores from the communication, daily living skills, socialization and motor skills domains and converted into the adaptive behavior composite standard score. Change in the adaptive behaviour composite standard score from baseline to week 24 is reported. Positive change indicates improvement. |
| Time Frame | Baseline and 24 Weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 participant was dropped from the analysis in the Omega-3 group as there was insufficient data due to early termination. |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Measure Participants | 18 | 19 |
| Mean (95% Confidence Interval) [units on a scale] |
2.8
|
-0.2
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Omega-3 Fatty Acids, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.09 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Title | Change From Baseline in the Preschool Language Scale (PLS-4) - Total Language |
|---|---|
| Description | The PLS-4 is a language measure that provides a global assessment of a child's language functioning abilities, receptive and expressive language. Secondary outcome measure domain: Total language standard score Total Language Standard Score Range: Minimum range: 50 (lower language abilities) Maximum range: 150 (higher language abilities) The total language standard score is computed from a sum of the auditory comprehension and expressive communication standard scores, then converted into the total language standard score. Change of total language standard scores from baseline to week 24 is reported. Positive change indicates improvement |
| Time Frame | Baseline and 24 Weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| 1 participant was dropped from the analysis in the Omega-3 group as there was insufficient data due to early termination. |
| Arm/Group Title | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Arm/Group Description | Participants started at 0.75 g of EPA + DHA (1.875 ml once a day) of liquid formulation of NutraSea HP. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The NutraSea HP formulation is a naturally derived fish oil that is extracted, isolated, and processed to contain EPA/DHA in the ratio of 3:1. It has a lemon flavor. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. |
| Measure Participants | 18 | 19 |
| Mean (95% Confidence Interval) [units on a scale] |
0.7
|
-0.6
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Omega-3 Fatty Acids, Placebo |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.6 |
| Comments | ||
| Method | Regression, Linear | |
| Comments | ||
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Omega-3 Fatty Acids | Placebo | ||
| Arm/Group Description | Children will be administered 3.75ml of the liquid formulation of NutraSea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process. Omega-3 Fatty Acids: Children will be administered 3.75ml of the liquid formulation of NutraSea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process. | Participants started at 0.75 g (1.875 ml once a day) of liquid formulation of placebo. If this was well tolerated, the dose was doubled to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada guidelines for maximum dose for this age group. The placebo had the same physical characteristics as the medication (NutraSea HP) but contained refined olive oil and medium chain triglycerides. The placebo has a lemon flavor. | ||
All Cause Mortality |
||||
| Omega-3 Fatty Acids | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Omega-3 Fatty Acids | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/19 (0%) | 0/19 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Omega-3 Fatty Acids | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 19/19 (100%) | 19/19 (100%) | ||
| Ear and labyrinth disorders | ||||
| Earache | 3/19 (15.8%) | 3 | 0/19 (0%) | 0 |
| Eye disorders | ||||
| Eye Swelling | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Nearsightedness | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Red Eyes | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Gastrointestinal disorders | ||||
| Abdominal Pain | 3/19 (15.8%) | 6 | 3/19 (15.8%) | 4 |
| Regurgitation | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Vomiting | 4/19 (21.1%) | 4 | 3/19 (15.8%) | 3 |
| Diarrhea | 5/19 (26.3%) | 5 | 8/19 (42.1%) | 9 |
| Constipation | 6/19 (31.6%) | 7 | 6/19 (31.6%) | 7 |
| Gastroenteritis | 1/19 (5.3%) | 1 | 2/19 (10.5%) | 2 |
| General disorders | ||||
| Decreased Energy | 3/19 (15.8%) | 4 | 2/19 (10.5%) | 2 |
| Infections and infestations | ||||
| Upper Respiratory Infection | 16/19 (84.2%) | 23 | 14/19 (73.7%) | 24 |
| Fever | 4/19 (21.1%) | 4 | 4/19 (21.1%) | 5 |
| Ear Infection | 1/19 (5.3%) | 1 | 3/19 (15.8%) | 3 |
| Skin Infection | 1/19 (5.3%) | 1 | 1/19 (5.3%) | 1 |
| Hand Mouth Foot Disease | 0/19 (0%) | 0 | 1/19 (5.3%) | 2 |
| Roseola | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Bronchiolitis | 0/19 (0%) | 0 | 3/19 (15.8%) | 3 |
| Hand Mouth Foot Disease | 0/19 (0%) | 0 | 1/19 (5.3%) | 2 |
| Injury, poisoning and procedural complications | ||||
| Left Knee Injury | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Metabolism and nutrition disorders | ||||
| Increased Appetite | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Decreased Appetite | 6/19 (31.6%) | 7 | 2/19 (10.5%) | 3 |
| Decreased Dietary Variety | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Muscle Aches | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Right Leg Internal Rotation | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Nervous system disorders | ||||
| Headache | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Initial Insomnia | 5/19 (26.3%) | 6 | 4/19 (21.1%) | 4 |
| Mid-cycle Insomnia | 3/19 (15.8%) | 6 | 2/19 (10.5%) | 3 |
| Early Awakening | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Non-restorative Sleep | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Nightmares | 1/19 (5.3%) | 1 | 1/19 (5.3%) | 1 |
| Psychiatric disorders | ||||
| Overactivity | 3/19 (15.8%) | 3 | 0/19 (0%) | 0 |
| Social Communicative Intent Loss | 1/19 (5.3%) | 1 | 1/19 (5.3%) | 1 |
| Staring Spell | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Increased Emotional Lability | 1/19 (5.3%) | 1 | 2/19 (10.5%) | 3 |
| Increased Irritability/Anger/Aggression | 7/19 (36.8%) | 10 | 2/19 (10.5%) | 4 |
| Stuttering | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Renal and urinary disorders | ||||
| Daytime Wetting | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Pain on Urination | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Change in Urine Colour | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Nose Bleed | 0/19 (0%) | 0 | 3/19 (15.8%) | 3 |
| Nasal Congestion | 1/19 (5.3%) | 2 | 1/19 (5.3%) | 1 |
| Cough | 2/19 (10.5%) | 3 | 3/19 (15.8%) | 4 |
| Skin and subcutaneous tissue disorders | ||||
| Rash | 6/19 (31.6%) | 10 | 9/19 (47.4%) | 9 |
| Eczema | 2/19 (10.5%) | 2 | 3/19 (15.8%) | 4 |
| Bruising | 3/19 (15.8%) | 4 | 1/19 (5.3%) | 2 |
| Dry Skin | 1/19 (5.3%) | 1 | 2/19 (10.5%) | 2 |
| Flaky Scalp | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
| Surgical and medical procedures | ||||
| Eye Surgery | 1/19 (5.3%) | 1 | 0/19 (0%) | 0 |
| Tonsillectomy | 0/19 (0%) | 0 | 1/19 (5.3%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Evdokia Anagnostou |
|---|---|
| Organization | Holland Bloorview Kids Rehabilitation Hospital |
| Phone | 416-425-6220 ext 6005 |
| eanagnostou@hollandbloorview.ca |
- 09-018